Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002428 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects
A Phase 1 study of HIV Infections, sponsored by United Biomedical.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Study location
NCT00002428: Completed Phase 1 study of HIV Infections, sponsored by United Biomedical.
NCT00002428 is a Phase 1 study of HIV Infections that has completed, run by United Biomedical. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002428, a Phase 1 study of HIV Infections, has completed, sponsored by United Biomedical.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1
- Study location
Study Summary
To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in intermediate or higher risk HIV-negative volunteers.
Conditions Studied
Interventions
- BIOLOGICAL HIV-1 Peptide Vaccine, Microparticulate Monovalent
- BIOLOGICAL rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine
Study Locations (1)
California
- Univ of California at San Francisco Gen Hosp - San Francisco
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002428
The ClinicalTrials.gov registry entry for NCT00002428 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is United Biomedical, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which HIV-1 Peptide Vaccine, Microparticulate Monovalent is the first listed.
NCT00002428 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00002428 about?
NCT00002428 is a clinical study titled "A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects". To evaluate the safety and immunogenicity of a combination of microparticulate monovalent HIV-1 MN synthetic branched peptide candidate vaccine for oral administration and monovalent HIV-1 MN synthetic branched peptide vaccine in alum for intramuscular administration in intermediate or higher risk H...
What is the current status of trial NCT00002428?
This trial is currently completed. It is a Phase 1 study.
What conditions does trial NCT00002428 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002428?
The interventions under investigation include: HIV-1 Peptide Vaccine, Microparticulate Monovalent (BIOLOGICAL), rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002428?
This trial is sponsored by United Biomedical, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002428 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
RECRUITING · Phase 1
-
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
RECRUITING · Phase 1
-
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
RECRUITING · Phase 1
-
First Time in Human Study of Long Acting VH4524184 Formulations
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.